Application of eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in treatment of liver injury

A technology of erf3b-36 and release factors, which is applied in the field of biopharmaceuticals, can solve the problems of limited fat elimination, inability to remove liver fat, liver cell damage, etc., and achieve the effects of less toxic side effects, good preventive and therapeutic effects, and reduced content

Active Publication Date: 2014-08-27
河北意和医学检验实验室有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, patients with moderate-to-severe fatty liver cannot effectively remove liver fat through non-drug therapy. Antioxidants such as vitamin E and vitamin C, liver cell protective agents, choleretic and hepatoprotective drugs, cytokine inhibitors and CYP inhibitors, etc.
However, most lipid-lowering drugs have limited effect on the elimination of intrahepatic fat, and many lipid-lowering drugs can cause different degrees of liver cell damage, so the role and status of lipid-lowering drugs in the treatment of fatty liver are still controversial

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in treatment of liver injury
  • Application of eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in treatment of liver injury
  • Application of eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in treatment of liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] eRF3b injection in Example 1 (human eRF3b fragment (eRF3b-36) solution):

[0059] Human eRF3b fragment (eRF3b-36) lyophilized powder 2mg

[0060] Sterile normal saline 1ml

[0061] Pipette repeatedly with a pipette until the lyophilized powder is completely dissolved, aliquot into 100ul tubes, and store at -20°C. Before use, dilute with sterile saline according to the needs of the experiment.

[0062] Preparation of 4% paraformaldehyde solution:

[0063]

[0064] Stir the above components fully at 50°C until they are completely dissolved, adjust the pH to 7.4, and add double distilled water to make up to 1L.

[0065] Male Balb / c inbred mice (6-8 weeks old) were purchased from the Experimental Animal Center of Hebei Medical University.

[0066] Male SD rats (180-200 g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.

[0067] Preparation of PI staining solution: 129.6ml of normal saline, 10mg of PI, 2mg of RNase, 1.0% by volume o...

Embodiment 2

[0076] The eRF3b injection in embodiment 2:

[0077] Human eRF3b fragment (eRF3b-36) lyophilized powder 5mg

[0078] Sterile normal saline 2ml

[0079] Pipette repeatedly with the pipette until the lyophilized powder is completely dissolved, and store at -20°C. Dispense 500 μl per tube into 1.5ml EP tubes and dilute with sterile saline to the administration concentration before use.

[0080] The acute liver injury induced by Con A in Example 1 is acute immune liver injury.

[0081] The physiological saline in the following examples is sterile physiological saline.

[0082] Example 1. Application of human eRF3b fragment (eRF3b-36) in the treatment of acute liver injury

[0083] 1. Prevention experiment

[0084] (1) Experimental grouping

[0085] 56 male Balb / c inbred mice (6-8 weeks old) were randomly divided into 7 groups, namely normal control group, ConA model group, dexamethasone positive control group, eRF3b-361 group, eRF3b-362 group , eRF3b-363 group and eRF3b-364...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of a eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in the treatment of liver injury. The invention discloses application of the eRF3b-36 in the preparation of products for preventing and/or treating liver injury. According to the application, the eRF3b-36 has a good prevention and treatment effect on Con A induced acute hepatitis; in addition, shown by treatment research on fatty liver, dosed groups of the eRF3b-36 exert a good protecting effect on the liver regardless of whether in a serological index or hepatic histopathology, the level of ALT, AST, CHOL, TG and TBIL in blood serum can be remarkably lowered, and the content of free fat in liver tissue can be lowered; thus, a new possible direction and specific measures are provided for clinical liver disease treatment.

Description

technical field [0001] The invention relates to the application of eukaryotic peptide chain release factor 3b fragment (eRF3b-36) in the treatment of liver injury, which belongs to the field of biopharmaceuticals. Background technique [0002] Liver disease is an important public health problem. Many reasons, such as viruses, chemical substances, drugs, alcohol, genetic factors or autoimmune system, can lead to liver lesions. Long-term liver damage will eventually develop into liver failure. Although the development of liver disease is caused by many different pathogens and complex pathogenesis, recent studies have shown that the immune system plays a key role in the pathogenesis of most etiologies. Acute liver injury induced by intravenous Con A (acute immune liver injury) is an ideal animal model mimicking the pathophysiology of human viral and autoimmune hepatitis to study human T cell-mediated liver disease. The characteristic manifestations of Con A-induced hepatitis a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P1/16
Inventor 刘殿武李曼王剑员美娜刘志鹏王佳梁晨
Owner 河北意和医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap